Sigma-Aldrich this week announced the addition of 2,300 antibodies to its Prestige Antibodies line, bringing the total number of antibodies sold under that brand to 6,100.
Prestige Antibodies are the result of a partnership forged by Sigma-Aldrich and Atlas Antibodies, the commercial arm of the Human Proteome Resource, to commercialize antibodies that are among the most highly characterized on the market [see PM 02/14/08]. The Human Proteome Resource runs the Human Protein Atlas.
The goal of the partnership is to develop at least one antibody against each of the 22,000 non-redundant human proteins by 2015.
The addition of the 2,300 antibodies, which follows an addition of more than 2,000 antibodies last August, is a significant step in Sigma-Aldrich's "long-term plan to lead the industry in high-quality antibody content," David Smoller, president of the company's Resarch Biotech Business Unit, said in a statement.
ForteBio this week launched two high-throughput label-free instruments, the Octet Red384 for protein, peptide, and small molecule screening, and the Octet QK384 for protein and antibody assays.
Both instruments enable 384-well detection, 16-channel simultaneous readout, biosensor regeneration and re-racking, and automation capabilities for biotherapeutic and pharmaceutical drug-discovery assays, ForteBio, based in Menlo Park, Calif., said in a statement.
The new systems are supported by version 6 of the Octet software for data acquisition and analysis. The software includes enhancements such as a 2:1 heterogeneous ligand binding model, data tracking, and processing capabilities that assist high-throughput screening, the firm said.
In a statement, Christopher Silva, vice president of marketing for ForteBio, said the two systems will offer efficiency improvements "for life-science research applications that have traditionally been conducted using ELISA or SPR-based methods." IgG titer determination can be completed in less than 20 minutes compared to four to five hours on an ELISA, he said, while protein kinetic screening and characterization on a 384-well plate can be finished in about two hours.
Microarray instrument and scanner company Arrayit this week said its patented testing procedure, Variation Identification Platform, is ready for commercialization.
The Sunnyvale, Calif., company said in a statement that VIP allows clinicians to test up to 100,000 patients "against a single disease state health condition" by printing out bio-information on a single slide and then drawing a diagnosis for each patient.
Arrayit said it is now positioned to move the technology from research to clinical applications "and beyond."